P E Harris
Overview
Explore the profile of P E Harris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
880
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Herst C, Burkholz S, Sidney J, Sette A, Harris P, Massey S, et al.
Vaccine
. 2020 May;
38(28):4464-4475.
PMID: 32418793
The 2013-2016 West Africa EBOV epidemic was the biggest EBOV outbreak to date. An analysis of virus-specific CD8+ T-cell immunity in 30 survivors showed that 26 of those individuals had...
2.
Wetherall M, Corbett I, Ince P, James R, Daniels M, Harris P, et al.
Endocr Pathol
. 2020 May;
2(4):210-213.
PMID: 32357635
Thec-erbB-2 proto-oncogene encodes a 190-kD putative membrane receptor that shows considerable homology to the epidermal growth factor (EGF) receptor.c-erbB-2 is overexpressed in many human tumors but has not previously been...
3.
Harris P, Cooper K, Relton C, Thomas K
Int J Clin Pract
. 2012 Sep;
66(10):924-39.
PMID: 22994327
Objectives: To update previous systematic reviews of 12-month prevalence of complementary and alternative medicine (CAM) use by general populations; to explore trends in CAM use by national populations; to develop...
4.
Harris P, Leibel R
Diabetes Obes Metab
. 2012 Aug;
14 Suppl 3:91-100.
PMID: 22928569
Here, we outline how islet cells use autocrine and paracrine 'circuits' of classical neurotransmitters and their corresponding receptors and transporters to communicate with vicinal β-cells to regulate glucose-stimulated insulin secretion....
5.
Chammas N, Chambers S, Harris P
Pituitary
. 2008 Apr;
11(3):271-8.
PMID: 18425583
Objective: To examine the utility of the GnRH (gonadotrophin-releasing hormone) test in the management of patients with pituitary and parapituitary lesions. Patients And Methods: A 5-year retrospective study of LH...
6.
Gilbert J, KETCHEN M, Kane P, Mason T, Baister E, Monaghan M, et al.
Pituitary
. 2003 Dec;
6(1):11-8.
PMID: 14674719
Aim: Somatostatin analogues are normally used as adjunctive therapy to surgery and radiotherapy in management of acromegaly. We studied the effects of de novo OCT-LAR treatment on growth hormone (GH)...
7.
Bevan J, Atkin S, Atkinson A, Bouloux P, Hanna F, Harris P, et al.
J Clin Endocrinol Metab
. 2002 Oct;
87(10):4554-63.
PMID: 12364434
Conventional surgery and radiotherapy for acromegaly have limitations. There are few data on the use of the somatostatin analog octreotide (Oct) as primary medical therapy. An open prospective study of...
8.
Best L, Harris P, Spriggs E
Clin Genet
. 2001 Sep;
60(1):68-72.
PMID: 11531973
Homozygosity for the C282Y mutation of the HFE gene is a highly significant risk factor for the development of hereditary hemochromatosis (HH) and the majority of patients with HH have...
9.
Moschella F, Maffei A, Catanzaro R, Papadopoulos K, Skerrett D, Hesdorffer C, et al.
Br J Haematol
. 2001 Sep;
114(2):444-57.
PMID: 11529869
Using cDNA arrays, we characterized patterns of gene expression in populations of human dendritic cells (DCs) produced for clinical use. Culture and maturation induction of myeloid adherent cells under serum-free...
10.
Cancedda C, LeMaoult J, Harris P, Suciu-Foca N, Cortesini R
Transplant Proc
. 2001 Mar;
33(1-2):165-6.
PMID: 11266761
No abstract available.